Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Reduce Bleeding in Premenopausal Women With Abnormal Uterine Bleeding: A Pilot Study.

Trial Profile

Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Reduce Bleeding in Premenopausal Women With Abnormal Uterine Bleeding: A Pilot Study.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Menorrhagia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top